MEDICINOVA INITIATES TRIAL OF MN-246

A A

MediciNova has announced the initiation of a Phase I clinical trial to determine the safety, tolerability and pharmacokinetics of its novel oral treatment for urinary incontinence (MN-246) in healthy human volunteers.

MN-246 is a novel, potent and highly selective Beta3-adrenergic receptor agonist under development by the company for the treatment of urinary incontinence. It represents a potential new approach to treating urinary incontinence and may have advantages over existing therapies, including improvements in efficacy through increases in bladder volume with decreases in involuntary bladder contractions and the absence of anti-cholinergic side effects such as dry mouth.